Abstract: A method for treating biomass to be supplied to a fermentation system for the production of a fermentation product is disclosed. The method comprises the steps of pre-treating the biomass into pre-treated biomass; separating the pre-treated biomass into a first component comprising glucan and a second component comprising sugars; providing a combined component comprising at least a portion of the first component and at least a portion of the second component; and treating the combined component of the pre-treated biomass into a treated component comprising glucose by application of an enzyme formulation. A system for treating biomass to be supplied to a fermentation system for the production of a fermentation product is also disclosed. The system comprises an apparatus configured to pre-treat the biomass; a separator configured to separate the pre-treated biomass; and a vessel configured to contain a combined component.
Abstract: A method for separating and purifying recombinant human serum albumin (rHSA) from transgenic rice grain, sequentially comprising the steps of: 1) subjecting crude extract of rHSA to cation exchange chromatography to obtain primary product I; 2) subjecting the primary product I to anion exchange chromatography to obtain secondary product II; 3) subjecting the secondary product II to hydrophobic chromatography to obtain purified rHSA. The method may further comprise a step of ceramic hydroxyapatite chromatography prior to the hydrophobic chromatography. The method has the advantages of low cost and easy operation. The resultant rHSA has a purity of about 99% by HPLC.
Type:
Grant
Filed:
August 10, 2011
Date of Patent:
May 5, 2015
Assignee:
Healthgen Biotechnology Co., Ltd.
Inventors:
Daichang Yang, Yang He, Guangfei Li, Jingru Liu
Abstract: The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, Staphylococcus aureus Protein A (SpA), as well as methods of using the same.
Type:
Grant
Filed:
November 6, 2014
Date of Patent:
April 28, 2015
Assignee:
EMD Millipore Corporation
Inventors:
Shari Spector, Robert Smith, Joe Orlando, Nanying Bian
Abstract: The invention provides variants of the Clostridium thermocellum endoglucanase (CelG) that have improved endoglucanase activity compared to the wild type enzyme. Also provided are related polynucleotides, compositions, vectors, host cells, and methods of use.
Type:
Grant
Filed:
March 10, 2010
Date of Patent:
April 14, 2015
Assignee:
Codexis, Inc.
Inventors:
Jie Yang, Xiyun Zhang, Ish Kumar Dhawan, Andrew Shaw
Abstract: This invention relates to the use of microcystins as agents for treatment of cancer. Also provided are methods of screening for microcystins with improved cytotoxicity.
Type:
Grant
Filed:
May 10, 2007
Date of Patent:
April 14, 2015
Assignee:
University of Kentucky Research Foundation
Inventors:
Noel R. Monks, Shuqian Liu, Jeffrey A. Moscow
Abstract: The present invention relates to pectate lyase variants exhibiting alterations relative to a parent enzyme exhibiting pectate lyase activity as its major enzymatic activity; to a method of producing such enzymes; and to methods for using such enzymes in the textile, detergent and cellulose fiber processing industries. Compared to the parent enzyme, the pectate lyase variants of the present invention exhibit improved stability in detergents.
Type:
Grant
Filed:
September 13, 2013
Date of Patent:
April 14, 2015
Assignee:
Novozymes A/S
Inventors:
Sanne Schoeder Glad, Carsten Andersen, Torben Vedel Borchert, Katja Salomon Johansen, Henrik Frisner, Mads Eskelund Bjornvad, Thomas Thisted
Abstract: Innovative non-surgical methods and compositions are provided for administering PDT to promote tissue regeneration or augmentation while minimizing scarring and risk of infection. Among several areas of application, is the treatment of acute and chronic wounds which have afflicted epidermal and connective tissue layers of the body. Another application area is as cosmetic surgery/treatments, including: reducing wrinkles, sulcus, scars (acne or traumatic caused), sequelae cellulite, as well as for other skin irregularities, to give a smoother skin surface. This invention consists of a collagen based or other suitable biodegradable supporting matrix which is embedded with a liposomal loaded photosensitizer. In one embodiment of this invention a liposomal formulated photosensitizer is first injected at the site followed by collagen implantation and PDT treatment. In another embodiment a liposomal formulated photosensitizer is incorporated in the collagen.
Type:
Grant
Filed:
January 5, 2007
Date of Patent:
April 7, 2015
Assignee:
Biolitec Pharma Marketing Ltd
Inventors:
Wolfgang Neuberger, Volker Albrecht, Danilo Castro
Abstract: Compositions and methods are provided that are useful for the delivery, including transdermal delivery, of biologically active agents, including nucleic acids and therapeutic proteins including insulin, larger therapeutic proteins such as botulinum toxin and other biologically active agents such as a therapeutic protein which does not therapeutically alter blood glucose levels, a therapeutic nucleic acid-based agent, a non-protein non-nucleic acid therapeutic agent such as an antifungal agent or alternately an agent for immunization. The compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.
Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing obesity, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the animal or human subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing obesity.
Type:
Grant
Filed:
September 26, 2011
Date of Patent:
February 17, 2015
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jaekel, Christoph Meyer
Abstract: The invention provides for a receptor, capable of binding to a target molecule, linked to a hygroscopic polymer or hydrogel; and the use of this receptor in a device for detecting the target molecule in a gaseous and/or liquid phase. The invention also provides for a method for detecting the presence of a target molecule in the gas phase using the device. In particular, the receptor can be a peptide capable of binding a 2,4,6-trinitrotoluene (TNT) or 2,4,-dinitrotoluene (DNT).
Type:
Grant
Filed:
October 13, 2009
Date of Patent:
February 17, 2015
Assignee:
The Regents of the University of California
Inventors:
Justyn W. Jaworski, Seung-Wuk Lee, Arunava Majumdar, Digvijay A. Raorane
Abstract: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
Abstract: Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.
Abstract: Fatty acid 13-hydroperoxide lyase proteins which have been modified with respect to a previously described guava 13-hydroperoxide lyase and the nucleic acid sequences encoding these proteins. Also, recombinant nucleic acid molecules for expressing the modified 13-hydroperoxide lyases and methods of using such lyases in the field of organic synthesis.
Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
Type:
Grant
Filed:
September 16, 2011
Date of Patent:
December 30, 2014
Assignee:
MannKind Corporation
Inventors:
Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
Abstract: Provided are compositions comprising recombinant DNA polymerases that include amino acid substitutions, insertions, deletions, and/or exogenous features that confer modified properties upon the polymerase for enhanced single molecule sequencing. Such properties include increased resistance to photodamage, and can also include enhanced metal ion coordination, reduced exonuclease activity, reduced reaction rates at one or more steps of the polymerase kinetic cycle, decreased branching fraction, altered cofactor selectivity, increased yield, increased thermostability, increased accuracy, increased speed, increased readlength, and the like. Also provided are nucleic acids which encode the polymerases with the aforementioned phenotypes, as well as methods of using such polymerases to make a DNA or to sequence a DNA template.
Type:
Grant
Filed:
January 31, 2013
Date of Patent:
December 9, 2014
Assignee:
Pacific Biosciences of California, Inc.
Inventors:
Satwik Kamtekar, Arek Bibillo, Keith Bjornson, Fred Christians, Colleen Cutcliffe, Jeremiah Hanes, Lei Jia, Walter Lee, Erik Miller, Pranav Patel
Abstract: The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug.
Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are compositions and methods related to components of a CRISPR complex particularly comprising a Cas ortholog enzyme.
Type:
Grant
Filed:
June 2, 2014
Date of Patent:
November 25, 2014
Assignees:
The Broad Institute Inc., Massachusetts Institute of Technology
Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are compositions and methods related to components of a CRISPR complex particularly comprising a Cas ortholog enzyme.
Type:
Grant
Filed:
June 2, 2014
Date of Patent:
November 18, 2014
Assignees:
The Broad Institute Inc., Massachusetts Institute of Technology